Needham Maintains Buy on Viridian Therapeutics, Lowers Price Target to $32

Benzinga Newsdesk www.benzinga.com Neutral 45.7%

Neg 0% Neu 45.7% Pos 0%

Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $42 to $32.